{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:58:48Z","timestamp":1794031128815,"version":"4.8.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Low-density lipoprotein cholesterol (LDL-C) is the pre-eminent target for the prevention and treatment of atherosclerotic cardiovascular disease (ASCVD). Despite the expansive evidence supporting therapeutic reductions in LDL-C with statin therapy, many high-risk patients do not achieve guideline-recommended treatment targets resulting in avoidable cardiovascular events and higher healthcare expenditures. Underutilization of effective LDL-C lowering is exacerbated by low adherence to statin therapy even among patients following an acute coronary event. Adjunctive therapies such as ezetimibe and PCSK9 monoclonal antibodies remain underutilized, and polypharmacy regimens used for the treatment of cardiovascular disease further increase challenges for patients. Although cardiovascular outcomes data are lacking, inclisiran, a small-interfering RNA (siRNA) targeting PCSK9 mRNA, is available for clinical use. Novel implementation approaches offer the opportunity for more durable or even potentially permanent solutions for lipoprotein-associated cardiovascular disease risk. As an adjunct to statins, these novel approaches may offer more durable approaches for the prevention of ASCVD events. In this review, we discuss the challenges of current LDL-C lowering therapies, achieving LDL-C targets and the necessity of novel approaches.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwaf123","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:22:08Z","timestamp":1741044128000},"page":"1136-1144","source":"Crossref","is-referenced-by-count":13,"title":["Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-9988","authenticated-orcid":false,"given":"Waqas A","family":"Malick","sequence":"first","affiliation":[{"name":"Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , Hospital Box 1030, One Gustave L. Levy Place, New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-3784","authenticated-orcid":false,"given":"Daein","family":"Choi","sequence":"additional","affiliation":[{"name":"Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , Hospital Box 1030, One Gustave L. Levy Place, New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-7223","authenticated-orcid":false,"given":"Anne","family":"Langsted","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-850X","authenticated-orcid":false,"given":"Vera","family":"Bittner","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Disease, University of Alabama at Birmingham , Birmingham, AL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-7220","authenticated-orcid":false,"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-6260","authenticated-orcid":false,"given":"Erik S G","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5599-0633","authenticated-orcid":false,"given":"Robert S","family":"Rosenson","sequence":"additional","affiliation":[{"name":"Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , Hospital Box 1030, One Gustave L. Levy Place, New York, NY 10029 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"2025092119522917700_zwaf123-B1","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B2","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","article-title":"Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries","volume":"2","author":"Colantonio","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2025092119522917700_zwaf123-B3","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"An assessment by the statin muscle safety task force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2025092119522917700_zwaf123-B4","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"2025092119522917700_zwaf123-B5","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1093\/eurheartj\/ehy182","article-title":"Adverse effects of statin therapy: perception vs. the evidence\u2014focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract","volume":"39","author":"Mach","year":"2018","journal-title":"Eur Heart J"},{"key":"2025092119522917700_zwaf123-B6","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1093\/eurheartj\/ehaa229","article-title":"From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases","volume":"41","author":"Landmesser","year":"2020","journal-title":"Eur Heart J"},{"key":"2025092119522917700_zwaf123-B7","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B8","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jamacardio.2021.3508","article-title":"Association between cumulative low-density lipoprotein cholesterol exposure during young adulthood and middle age and risk of cardiovascular events","volume":"6","author":"Zhang","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025092119522917700_zwaf123-B9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B10","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B11","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jacc.2023.02.038","article-title":"Familial hypercholesterolemia: challenges for a high-risk population: JACC focus seminar 1\/3","volume":"81","author":"Choi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B12","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-Year Follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092119522917700_zwaf123-B13","doi-asserted-by":"crossref","first-page":"100492","DOI":"10.1016\/j.ajpc.2023.100492","article-title":"Disparities in statin prescription among patients with severe hypercholesterolemia in an integrated healthcare system","volume":"14","author":"Jean-Marie","year":"2023","journal-title":"Am J Prev Cardiol"},{"key":"2025092119522917700_zwaf123-B14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mayocp.2023.09.016","article-title":"Trends of lipid concentrations, awareness, evaluation, and treatment in severe dyslipidemia in US adults","volume":"99","author":"Shetty","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"2025092119522917700_zwaf123-B15","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.jacc.2022.02.049","article-title":"Trends in high-intensity statin therapy after myocardial infarction among U.S. Adults, 2011\u20132019","volume":"79","author":"Colantonio","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/2047487315569401","article-title":"EUROASPIRE IV: a European society of cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","volume":"23","author":"Kotseva","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2025092119522917700_zwaf123-B17","doi-asserted-by":"crossref","first-page":"e001196","DOI":"10.1136\/openhrt-2019-001196","article-title":"ASPIRE-3-PREVENT: a cross-sectional survey of preventive care after a coronary event across the UK","volume":"7","author":"Jennings","year":"2020","journal-title":"Open Heart"},{"key":"2025092119522917700_zwaf123-B18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jacc.2020.05.048","article-title":"Atherosclerotic risk and statin use among patients with peripheral artery disease","volume":"76","author":"Colantonio","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/STROKEAHA.122.040536","article-title":"Lack of statin therapy and outcomes after ischemic stroke: a population-based study","volume":"54","author":"\u00c5ivo","year":"2023","journal-title":"Stroke"},{"key":"2025092119522917700_zwaf123-B20","doi-asserted-by":"crossref","first-page":"e010376","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025092119522917700_zwaf123-B21","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjcard.2018.05.016","article-title":"Willingness to be reinitiated on a statin (from the REasons for geographic and racial differences in stroke study)","volume":"122","author":"Mefford","year":"2018","journal-title":"Am J Cardiol"},{"key":"2025092119522917700_zwaf123-B22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Reith","year":"2022","journal-title":"Lancet"},{"key":"2025092119522917700_zwaf123-B23","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1056\/NEJMc2031173","article-title":"N-of-1 trial of a statin, placebo, or No treatment to assess Side effects","volume":"383","author":"Wood","year":"2020","journal-title":"N Engl J Med"},{"key":"2025092119522917700_zwaf123-B24","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/eurheartj\/ehaa1011","article-title":"Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study","volume":"42","author":"Schubert","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092119522917700_zwaf123-B25","first-page":"829","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"4","author":"Reith","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025092119522917700_zwaf123-B26","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B27","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"2025092119522917700_zwaf123-B28","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"2025092119522917700_zwaf123-B29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1161\/ATVBAHA.122.317963","article-title":"New approaches for targeting PCSK9: small-interfering ribonucleic acid and genome editing","volume":"43","author":"Oostveen","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2025092119522917700_zwaf123-B30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"2025092119522917700_zwaf123-B31","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","article-title":"An inclisiran first strategy vs usual care in patients with atherosclerosis","volume":"83","author":"Koren","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B32","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.jacc.2023.10.007","article-title":"Safety and tolerability of inclisiran for treatment of hypercholesterolemia in 7 clinical trials","volume":"82","author":"Wright","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B33","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025092119522917700_zwaf123-B34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"2025092119522917700_zwaf123-B35","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"2025092119522917700_zwaf123-B36","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"2025092119522917700_zwaf123-B37","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2023.02.034","article-title":"Clinical trial design for triglyceride-rich lipoprotein-lowering therapies: JACC focus seminar 3\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025092119522917700_zwaf123-B38","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2021.1810","article-title":"Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US","volume":"6","author":"Cannon","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2025092119522917700_zwaf123-B39","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2025092119522917700_zwaf123-B40","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.ajpc.2022.100336","article-title":"Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United States: a 2019 update","volume":"10","author":"Gu","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"2025092119522917700_zwaf123-B41","first-page":"e100201","article-title":"Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA\/ACC multi-society cholesterol guideline","volume":"21","author":"Alanaeme","year":"2022","journal-title":"Am Heart J Plus"},{"key":"2025092119522917700_zwaf123-B42","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS familial hypercholesterolaemia studies collaboration (FHSC)","volume":"398","author":"Vallejo-Vaz","year":"2021","journal-title":"Lancet"},{"key":"2025092119522917700_zwaf123-B43","doi-asserted-by":"crossref","first-page":"e008861","DOI":"10.1161\/CIRCOUTCOMES.121.008861","article-title":"Lipid-lowering therapy use and intensification among United States veterans following myocardial infarction or coronary revascularization between 2015 and 2019","volume":"15","author":"Zheutlin","year":"2022","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025092119522917700_zwaf123-B44","doi-asserted-by":"crossref","first-page":"e009988","DOI":"10.1161\/CIRCOUTCOMES.123.009988","article-title":"Trends in patient access to and utilization of prescribed PCSK9 inhibitors in a large US claims database from 2015 to 2021","volume":"17","author":"MacDougall","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025092119522917700_zwaf123-B45","first-page":"100036","article-title":"Death, long-term nursing home placement, and impoverishment after recurrent myocardial infarction","volume":"7","author":"Levitan","year":"2021","journal-title":"Am Heart J Plus"},{"key":"2025092119522917700_zwaf123-B46","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10557-023-07452-1","article-title":"Recurrent atherosclerotic cardiovascular disease events potentially prevented with guideline-recommended cholesterol-lowering therapy following myocardial infarction","volume":"38","author":"Sakhuja","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025092119522917700_zwaf123-B47","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10557-021-07268-x","article-title":"The projected impact of population-wide achievement of LDL cholesterol &lt;70\u2005mg\/dL on the number of recurrent events among US adults with ASCVD","volume":"37","author":"McKinley","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2025092119522917700_zwaf123-B48","doi-asserted-by":"crossref","first-page":"A12945","DOI":"10.1161\/circ.148.suppl_1.12945","article-title":"Abstract 12945: six-month adherence among early inclisiran initiators vs. Anti-PCSK9 mAbs users: a retrospective analysis of US claims databases","volume":"148","author":"Niu","year":"2023","journal-title":"Circulation"},{"key":"2025092119522917700_zwaf123-B49","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(25)00910-6","volume-title":"The Impact of Adherence to LDL-C Lowering Therapies on Cardiovascular Events Among Adults With Primary Hyperlipidemia, Heterozygous Familial Hypercholesterolemia, and Atherosclerotic Cardiovascular Disease","author":"Rosenson","year":"2025"},{"key":"2025092119522917700_zwaf123-B50","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"key":"2025092119522917700_zwaf123-B51","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"2025092119522917700_zwaf123-B52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","article-title":"Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial","volume":"17","author":"Ballantyne","year":"2023","journal-title":"J Clin Lipidol"},{"key":"2025092119522917700_zwaf123-B53","volume-title":"Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol\u2014Interim Results of the Phase 1b Heart-1 Trial. AHA Scientific Sessions","author":"Bellinger","year":"2023"},{"key":"2025092119522917700_zwaf123-B54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jacl.2021.08.001","article-title":"Race\/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction","volume":"15","author":"Colvin","year":"2021","journal-title":"J Clin Lipidol"},{"key":"2025092119522917700_zwaf123-B55","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjmed.2021.11.011","article-title":"Association of low-density lipoprotein testing after an atherosclerotic cardiovascular event with subsequent statin adherence and intensification","volume":"135","author":"Rana","year":"2022","journal-title":"Am J Med"},{"key":"2025092119522917700_zwaf123-B56","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.amjcard.2019.12.030","article-title":"Impact of lipid monitoring on treatment intensification of cholesterol lowering therapies (from the veterans affairs healthcare system)","volume":"125","author":"Jia","year":"2020","journal-title":"Am J Cardiol"},{"key":"2025092119522917700_zwaf123-B57","doi-asserted-by":"crossref","first-page":"e010335","DOI":"10.1161\/CIRCOUTCOMES.123.010335","article-title":"Pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID): a randomized clinical trial","volume":"17","author":"Shah","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2025092119522917700_zwaf123-B58","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s40256-022-00534-9","article-title":"Cost effectiveness of inclisiran in atherosclerotic cardiovascular patients with elevated low-density lipoprotein cholesterol despite statin use: a threshold analysis","volume":"22","author":"Desai","year":"2022","journal-title":"Am J Cardiovasc Drugs"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwaf123\/62279356\/zwaf123.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1136\/62279356\/zwaf123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/32\/13\/1136\/62279356\/zwaf123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T23:52:40Z","timestamp":1758498760000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/32\/13\/1136\/8052896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":58,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,3,5]]},"published-print":{"date-parts":[[2025,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwaf123","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,3,5]]}}}